Imedex: Education is the Best Medicine®

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

Great Debates and Updates in GI Malignancies

March 26-27, 2010

New York, New York, USA

The Westin New York at Times Square

CONTINUING MEDICAL EDUCATION

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 11.5 of AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Who Should Attend
This educational activity is designed for medical oncologists, gastroenterologists, pathologists, radiologists, and other physicians and healthcare professionals in active clinical practice who are interested and/or involved in the care of patients with GI cancers.

Objectives
After attending this educational activity, participants should be able to:

Describe recent advances in our understanding of the biology of common GI tumors
Discuss the current and future role of biologic and targeted therapies in managing GI cancers
Review the use of biomarkers in GI malignancies and their applicability to prognosis and treatment
Compare and contrast the various approaches to adjuvant therapy for pancreatic cancer patients following tumor resection
Comment on whether targeted agents have truly altered outcomes for patients with advanced HCC
Explain efforts to raise the current standard of care for patients with resected carcinomas of the gastroesophageal junction
Summarize the roles of surgical resection and systemic chemotherapy in managing patients with recurrent GIST
Review common adverse events of GI cancer treatments and devise appropriate approaches to their management
Integrate conventional and emerging therapeutic options into a higher level of patient care

FACULTY

Ghassan K. Abou-Alfa, MD
Memorial Sloan-Kettering Cancer Center
Weill Medical College at Cornell University
New York, New York

Lowell B. Anthony, MD
LSU Health Sciences Center
New Orleans, Louisiana

Al B. Benson III, MD, FACP
Northwestern University
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois

Jordan D. Berlin, MD
Vanderbilt University Medical Center
Nashville, Tennessee

Karen T. Brown, MD, FSIR
Memorial Sloan-Kettering Cancer Center
New York, New York

Michael Choti, MD
Johns Hopkins University School of Medicine
Baltimore, Maryland

Christopher H. Crane, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Lee M. Ellis, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Cathy Eng, MD, FACP
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Axel Grothey, MD
Mayo Clinic
Rochester, Minnesota

Daniel G. Haller, MD
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania

Howard S. Hochster, MD
New York University Cancer Center
New York, New York

David H. Ilson, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York

Robert G. Maki, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York

John L. Marshall, MD
Georgetown University
Washington, District of Columbia

David P. Ryan, MD
Massachusetts General Hospital
Boston, Massachusetts

James C. Yao, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Andrew X. Zhu, MD, PhD
Massachusetts General Hospital
Boston, Massachusetts

Friday, March 26, 2010

7:00 am
Registration and Continental Breakfast

8:00 am
Welcome and introduction
Axel Grothey, MD and Daniel G. Haller, MD

Session I: Colorectal Carcinoma
Moderator: Daniel G. Haller, MD

8:10 am
Debate: Following a CR or near CR in advanced CRC from chemotherapy plus bevacizumab, is there significant value in continuing bev as maintenance therapy?

Yes, it improves and prolongs response
Cathy Eng, MD, FACP

No, it merely adds additional cost and toxicity
Howard S. Hochster, MD

8:40 am
Hereditary GI cancer syndromes: Advances in genetics, surveillance and management
Howard S. Hochster, MD

9:10 am
Debate: How intensively should resected CRC patients who have completed adjuvant therapy be followed?

High intensity surveillance
Al B. Benson III, MD, FACP

Low intensity surveillance
David P. Ryan, MD

9:40 am
Debate: Can genomic and molecular markers stratify colon cancer patients by prognosis and predict response to therapy?

Yes: Al B. Benson III, MD, FACP

No: Daniel G. Haller, MD

10:10 am
Break

Session II: Hepato-Biliary Cancers
Moderator: James Epstein, MD

10:30 am
Debate: Is cisplatin-gemcitabine now the standard of care for advanced biliary tract cancer?

Yes, it is definitely the new standard
Ghassan K. Abou-Alfa, MD

Not so fast, we need confirmation of ABC-01/02 trials
David H. Ilson, MD, PhD

11:00 am
Debate: Have targeted agents significantly altered the long term outcome for advanced HCC?

Yes, they have achieved a major improvement in outcome
Ghassan K. Abou-Alfa, MD

No, only the best prognosis patients live a few extra months
Andrew X. Zhu, MD, PhD

11:30 am
What is the role of transarterial in HCC?
Karen T. Brown, MD, FSIR

12:30 am
Novel therapies for advanced HCC: What to do when sorafenib fails
Andrew X. Zhu, MD, PhD

12:30 pm
Lunch

Session III: Pancreatic Tumors
Moderator: Axel Grothey, MD

1:30 pm
Debate: What is the best adjuvant therapeutic approach for resected pancreatic carcinoma?

5-FU based adjuvant therapy
Jordan D. Berlin, MD

Gemcitabine based adjuvant therapy
David H. Ilson, MD, PhD

2:00 pm
Novel agents under development and evaluation for pancreatic adenocarcinoma: Molecular biology leading the way to novel therapeutics
Jordan D. Berlin, MD

2:30 pm
Neuroendocrine tumors: Recent advances and goals for the future
James C. Yao, MD

3:00 pm
Break

Session IV: Colorectal Carcinoma
Moderator: Daniel G. Haller, MD

3:30 pm
Anal carcinoma: Standards of care, the role of HPV, vaccines and novel therapies under evaluation
Cathy Eng, MD, FACP

4:00 pm
Debate: How should we manage resected stage III colon carcinoma in patients 70 years of age or older?

mFOLFOX6
Cathy Eng, MD, FACP

5-FU-leucovorin alone
Axel Grothey, MD

4:30 pm
Debate: How should patients with resectable liver-only metastatic CRC be managed?

Neoadjuvant systemic therapy followed by surgery
John L. Marshall, MD

Surgery followed by adjuvant systemic therapy
Michael Choti, MD

5:00 pm
Adjourn

Saturday, March 27, 2010

7:00 am
Registration and Continental Breakfast

8:00 am
Welcome and introduction
Axel Grothey, MD and Daniel G. Haller, MD

Session V: Gastro-Esophageal Adenocarcinoma
Moderator: Axel Grothey, MD

8:05 am
Debate What is the standard of care for adjuvant therapy of resected HER2-negative gastric and GE junction adenocarcinomas?

5-FU based chemoradiation
Jordan D. Berlin, MD

Combination chemotherapy alone
David H. Ilson, MD, PhD

8:35 am
Advanced gastro-esophageal HER2-positive adenocarcinoma: A case based discussion Three part clinical case beginning with neoadjuvant vs. adjuvant therapy discussion, followed by post adjuvant therapy recurrence, followed by management of post-trastuzumab recurrent disease
David P. Ryan, MD and Daniel G. Haller, MD

9:05 am
Break

Session VI: GIST
Moderator: James Epstein, MD

9:30 am
Debate: Does imatinib cure micro-metastases in resected GIST?

Yes
Lowell B. Anthony, MD

No
Robert G. Maki, MD, PhD

10:00 am
Debate: What is the most effective management of recurrent GIST?

Surgical resection followed by systemic therapy
Michael Choti, MD

Systemic therapy alone
Robert G. Maki, MD, PhD

Session VII: Colon Carcinoma
Moderator: Axel Grothey MD and Daniel G. Haller, MD

10:30 am
Debate: Should oxaliplatin be added to the standard pre-op flouropyrimidines-XRT regimen for locally advanced rectal adenocarcinoma?

Yes, the benefit outweighs any added toxicity
David P. Ryan, MD

No, the additional toxicity outweighs the benefit
Christopher H. Crane, MD

11:00 am
Lunch

12:00 pm
Adjuvant therapy for resected colon cancer: Where do we stand now?
John L. Marshall, MD

12:30 pm
Novel targets and novel agents under development and evaluation for CRC
Lee M. Ellis, MD

1:00 pm
Debate: What should the role of RFA be in liver-only metastatic CRC?

RFA is underutilized
Karen T. Brown, MD, FSIR

RFA is over-utilized
Michael Choti, MD

1:30 pm
Debate: Is stage II colon cancer a different disease than stage III or merely an earlier stage of the same disease?

Stage II and III are biologically different diseases
Axel Grothey, MD

Stage II is an earlier stage of the same disease as stage III
John L. Marshall, MD

2:00 pm
Adjourn

Registration Fees

Regular $150
If payment received by March 18, 2010

Full/Onsite: $250
If payment received after March 18, 2010

Nurses/Residents/Students $75
*proof of eligibility must accompany registration

Register
You may register online by Thursday, March 18, 2010 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting. Please register onsite after this date.

Payment
To pre-register, registration and payment must be received no later than Thursday, March 18, 2010. Contact Imedex at +1 (678) 242 0906 or visit our website to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions
Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda.

Cancellation
For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than Thursday, March 18, 2010. The amount of registration fees remitted, minus a $50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after Thursday, March 18, 2010.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

The Westin New York at Times Square
270 West 43rd Street
New York, New York 10036
Tel.: +1 (212) 201 2700
Fax: +1 (212) 201 2701
http://www.starwoodmeeting.com/Book/greatdebatesandupd

The Westin New York at Times Square is located at 43rd Street and 8th Avenue, in the heart of the Broadway District with 40 theatres within walking distance. It is surrounded by the New York fashion, financial and commercial districts with easy access to the city’s subway system and within blocks of Penn Station and Grand Central Station. It is close to spectacular sights, city landmarks and incredible shopping.

For the convenience of attendees, a limited number of rooms have been reserved until March 4, 2010 at a discounted rate of $199.00 single/double occupancy in a ‘Traditional Room’ plus tax, currently at 14.75% plus $3.50 (NY City Occupancy Tax/Javits Center fee). This rate is not guaranteed outside the conference dates or after March 4, 2010.

To reserve your room please contact The Westin New York at Times Square reservations department at (888) 627-7149 for callers in the US and Canada and (212) 201-2700 for callers in all other regions. To receive the group rate, callers must identify themselves as being with the Great Debates and Updates in GI Malignancies group. Internet users must copy and paste the following link into a web browser: http://www.starwoodmeeting.com/Book/greatdebatesandupd . Reservation requests received after March 4, 2010 may not be guaranteed the group rate. Reservations requests received after March 4, 2010, will be accepted on a space available basis at the hotel’s published rates. Guest wishing to avoid an early departure fee of $100 must advise the hotel at or before check-in of any changes in the length of stay.

LETTER FROM THE CHAIRS

Dear Colleague,

We invite you to join us in New York City this March for Great Debates and Updates in GI Malignancies.

This meeting is a different kind of educational event – one we know you will enjoy and learn from. Recognized thought leaders engage in lively and interactive debates over some of the most controversial topics in the field and offer selected didactic presentations on the latest developments in colorectal cancer, GIST, pancreatic cancer, upper GI malignancies and more. Faculty and audience discussion is encouraged with a focus on how new information fits into current community practice in the field, providing you with the opportunity to learn how experts in the field manage their patients. New debates and topics this year will offer valuable information for repeat attendees as well as those new to the meeting.

The unique and instructive format of Great Debates and Updates in GI Malignancies will keep you up to date in the field and give you expert insight into the management of your GI patients. We hope to see you there!

Sincerely,

Axel Grothey, MD Daniel G. Haller, MD

Quotes from Past Participants
“Amazing cutting-edge discussion”
“Enjoyed the interaction among the faculty following the presentations”
“Debates were very stimulating; I was impressed with how serious the speakers took their side of the debate”
“Excellent review of data on both sides of difficult questions”
“Very well done conference with quality faculty”
“Excellent state of the art overview”

Important Dates
Hotel Reservation Deadline
Thursday, March 4, 2010

Online Registration Deadline
Thursday, March 18, 2010

Conference Dates
March 26 - 27, 2010

Endorsed by

CHAIRS

Axel Grothey, MD
Mayo Clinic
Rochester, Minnesota

Daniel G. Haller, MD
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania

MODERATOR

James Epstein, MD
Senior Medical Advisor Imedex, LLC
Alpharetta, Georgia

ORGANIZER

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

The following companies have provided an educational grant in support of this Conference:

PLATINUM

Genentech BioOncology and OSI Oncology

GOLD

BRONZE

CORPORATE

Bayer

Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1(770) 751 7332 or by email at cme@imedex.com.

The following companies are exhibitors at this Conference:

Opportunities are available to companies interested in exhibiting at this conference. For more information, please contact Cori Gunter at +1(678) 242 0712, or by email at c.gunter@imedex.com.